Olink is a company that provides proteomics solutions, focusing on the development and application of technologies for protein biomarker discovery and validation. The company offers a range of products, including the Olink Reveal, Olink Explore, and Olink Target panels, which enable researchers to measure thousands of proteins in a single sample. These products utilize a proprietary technology called Proximity Extension Assay (PEA) to detect and quantify proteins in various biological samples, such as plasma, serum, and cerebrospinal fluid. Olink's solutions cater to various research areas, including oncology, immunology, neuroscience, and cardiovascular disease, and are designed to support the discovery and development of biomarkers for disease diagnosis, prognosis, and treatment monitoring. By providing high-throughput, sensitive, and specific protein measurement capabilities, Olink aims to empower researchers and scientists to advance their understanding of human biology and disease mechanisms.

Olink Proteomics is a Swedish company dedicated to innovation, quality, rigor and transparency, providing outstanding products and services for human protein biomarker discovery. The company has a successful history of developing molecular technologies, with a broad IP portfolio. Many of these have been commercialized through out-licensing to industry leading partners such as Affymetrix, Life Technologies, and through the spin-out companies Qlinea and Halo Genomics (now part of Agilent). Olink sold its highly successful Duolink product line for in situ detection of proteins to Sigma-Aldrich in 2015. From 2016, Olink Proteomics focuses entirely on developing and expanding its platform of high-multiplex immunoassay panels for protein biomarker discovery.

High-throughput Multiplex array, simultaneous detection of 48, 96, > 1536 proteins per sample

2004